8-KEarnings & ResultsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Jun 30, 2021)

Filed June 30, 2021For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on June 30, 2021, to update its Listing Application with historical financial information for the years ended December 31, 2018, 2019, and 2020. This financial data was prepared in accordance with China Accounting Standards for Business Enterprises (PRC GAAP), which differ from U.S. GAAP. The filing includes additional details on gross profit margin ratios by product. A summary of the key differences between PRC GAAP and U.S. GAAP, along with U.S. GAAP-adjusted financial information, is provided as an exhibit (Exhibit 99.1). This report also includes forward-looking statements regarding a proposed issuance of RMB Shares, subject to market conditions and regulatory approvals. Investors are cautioned that this proposed issuance may not materialize and should exercise caution when dealing in the company's securities. Further updates will be provided as developments occur.

Key Highlights

  • 1Company updated its Listing Application with historical financial data for 2018-2020 prepared under PRC GAAP.
  • 2Key differences between PRC GAAP and U.S. GAAP, and U.S. GAAP-adjusted financial information are provided in Exhibit 99.1.
  • 3The filing includes product-specific gross profit margin ratio information for the reporting period.
  • 4The Listing Application is available in Chinese on the Shanghai Stock Exchange website.
  • 5Company disclosed forward-looking statements regarding a proposed issuance of RMB Shares.
  • 6The proposed RMB Share issuance is contingent on market conditions and regulatory approvals.
  • 7Investors are advised to exercise caution regarding the proposed RMB Share issuance due to uncertainty of its completion.

Frequently Asked Questions

The primary purpose of this 8-K filing is to update BeOne Medicines Ltd.'s Listing Application with historical financial information for the years 2018, 2019, and 2020, prepared according to PRC GAAP. It also serves to inform investors about a proposed issuance of RMB Shares and associated risks.

The filing highlights that the historical financial data is presented under PRC GAAP, which differs from U.S. GAAP. An exhibit (Exhibit 99.1) is provided to detail these differences and present financial information reconciled to U.S. GAAP, allowing investors to better understand the company's financial position according to U.S. accounting standards.

The proposed issuance of RMB Shares is subject to several conditions, including prevailing market conditions and the receipt of necessary regulatory approvals. The company explicitly states that there is no assurance that this issuance will proceed or when it might occur, and advises investors to exercise caution.

Detailed financial information, including a reconciliation to U.S. GAAP, is provided as Exhibit 99.1 to this 8-K filing. The Listing Application itself is available in Chinese on the Shanghai Stock Exchange website (www.sse.com.cn).